Novo Nordisk’s Pipeline Verdict Looms as Wegovy’s Formulary Edge Crumbles and Buybacks Fall Shor
As commercial pressures mount from Lilly rivals and patent expiries, Novo Nordisk’s upcoming data readouts for CagriSema and…
Novo Nordisk’s Three-Way Catalyst: Formulary Reset, EU Pill Approval, and Pipeline Data
Novo Nordisk’s Wegovy retains preferred CVS status but will share with Lilly’s Zepbound from Oct 2026. European regulators…
Novo Nordisk at a Tipping Point: Oral Wegovy Nears EU Market as US Formulary Edge Disappears
EMA recommends oral Wegovy approval as CVS Caremark removes Novo Nordisk’s exclusivity, adding Lilly’s drugs; stock plunges 44%…
Novo Nordisk at a Crossroads: Reimbursement Milestones and Pipeline Data Collide with Pricing and Fo
Novo Nordisk stock claws back from March low but faces pricing pressure in North America, reimbursement wins in…